Literature DB >> 21981683

Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration.

Rui Kuai1, Wenmin Yuan, Wanyu Li, Yao Qin, Jie Tang, Mingqing Yuan, Ling Fu, Rui Ran, Zhirong Zhang, Qin He.   

Abstract

A liposomal delivery system with a high efficiency of accumulation in tumor tissue and then transportation of the cargo into tumor cells was developed here and evaluated via systemic administration. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)(2000) (DSPE-PEG(2000))-TAT and protective DSPE-PEG(2000) modified liposomes possessing good stability in 50% FBS (fetal bovine serum) and good uptake efficiency were used as the basic formulation (TAT-SL; SL = stealth liposome), and then longer cysteine (Cys)-cleavable PEG(5000) was incorporated to modulate the function of TAT. All of the formulations to be used in vivo had sizes in a range of 80-100 nm and were stable in the presence of 50% FBS. Optical imaging showed that the incorporation of cleavable PEG(5000) into TAT-SL (i.e., C-TAT-SL) led to much more tumor accumulation and much less liver distribution compared with TAT-SL. The in vivo delivery profiles of C-TAT-SL were investigated using DiD as a fluorescent probe. Confocal laser scanning microscopy and flow cytometry showed that C-TAT-SL had a 48% higher (p < 0.001) delivery efficiency in the absence of Cys and a 130% higher (p < 0.001) delivery efficiency in the presence of Cys than the control (SL), indicating the successful targeted delivery of cargo was achieved by C-TAT-SL via systemic administration especially with a subsequent administration of Cys.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21981683     DOI: 10.1021/mp200100f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  20 in total

Review 1.  Effect of surface properties on liposomal siRNA delivery.

Authors:  Yuqiong Xia; Jie Tian; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

Review 2.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.

Authors:  Ling Li; Shuo Hu; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2018-04-18       Impact factor: 12.479

3.  Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma.

Authors:  Chuanyi Zheng; Chunyang Ma; Enqi Bai; Kun Yang; Ruxiang Xu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Harnessing the power of cell-penetrating peptides: activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents.

Authors:  Sarah R MacEwan; Ashutosh Chilkoti
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-09-13

Review 5.  Targeted delivery of nano-therapeutics for major disorders of the central nervous system.

Authors:  Huile Gao; Zhiqing Pang; Xinguo Jiang
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

6.  Mitochondrial Targeting Probes, Drug Conjugates, and Gene Therapeutics.

Authors:  Carmine Pasquale Cerrato; Tove Kivijärvi; Ülo Langel
Journal:  Methods Mol Biol       Date:  2022

7.  Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-17

8.  Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Drug Deliv       Date:  2012-05-10

9.  Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.

Authors:  Federico Perche; Vladimir P Torchilin
Journal:  J Drug Deliv       Date:  2013-03-07

10.  A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes.

Authors:  Jie Tang; Li Zhang; Han Fu; Qifang Kuang; Huile Gao; Zhirong Zhang; Qin He
Journal:  Acta Pharm Sin B       Date:  2014-01-23       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.